Stocks
Nkarta, Inc.NKTX
NASDAQHealthcareBiotechnology$1.79
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies for cancer. Its lead candidate, NKX101, targets acute myeloid leukemia and myelodysplastic syndromes, with early-stage data showing activity in relapsed or refractory patients. Investors track NKTX for its off-the-shelf allogeneic cell therapy platform, which aims to improve accessibility and manufacturing scalability compared to autologous CAR-T approaches.
52W Range: $1.66-$3.72
Congressional Interest in Nkarta, Inc. (NKTX)
No congressional trades have been disclosed for Nkarta, Inc. (NKTX) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading NKTX?
No congressional trades found for this stock.